Skip to main content

Press Releases View all 12 hits

Sobi expands Haemophilia development portfolio — elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec

Press Releases   •   Sep 19, 2014 12:06 GMT

Sobi has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company’s collaboration with Biogen Idec. “Although at an early stage, the XTEN technology has the potential to further extend FVIII half-life and could one day potentially become a next-generation long-acting factor for people with haemophilia A.”, said Geoffrey McDonough, CEO and President Sobi.

Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world

Press Releases   •   May 12, 2014 07:00 GMT

Biogen Idec and Sobi today announced their intent to produce one billion international units of clotting factor therapy for humanitarian aid programs in the developing world at the World Federation of Hemophilia 2014 World Congress.

Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate™ (rFVIIIFc) for haemophilia A

Press Releases   •   Apr 10, 2014 11:04 GMT

Biogen Idec and Sobi today released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.

US FDA approves Alprolix™

Press Releases   •   Mar 31, 2014 11:27 GMT

Sobi's partner Biogen Idec have announced that the US Food and Drug Administration (FDA) has approved Alprolix (Coagulation Factor IX (Recombinant), Fc fusion protein), the first recombinant, DNA derived haemophilia B therapy with prolonged circulation in the body.

Videos 1 hit

Biogen Idec and Sobi to donate 1 billion international units of clotting factor to support treatment of haemophilia in developing world

Biogen Idec and Sobi to d...

Biogen Idec and Sobi intend to produce one billion international units (IUs) of clotting factor therapy for humanitarian aid programs in ...

License Creative Commons Attribution
Download
Size

90.6 MB • 854 x 480 px